TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30167807
Drug: Intensive systolic
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systolic blood pressure treatment (< 120 mmHg) in the high-SBP group
Study: 30167807
Drug: Standard systolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systolic blood pressure treatment (< 140 mmHg) in the high-SBP group
Study: 20816187
Drug: Combination inhaler
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaler (125 microg fluticasone dipropionate and 25 microg salmeterol, 2 actuations twice daily)
Study: 20816187
Drug: Separate inhalers
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate inhalers (125 microg fluticasone dipropionate and 25 microg salmeterol, 2 actuations twice daily)
Study: 20816187
Drug: Combination inhaler
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaler vs. fluticasone
Study: 20816187
Drug: Combination inhaler
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaler vs. salmeterol
Study: 18077927
Drug: Paroxetine oral
Normalized name: paroxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine oral solution (20 mg/20 drops)
Study: 18077927
Drug: Paroxetine tablets
Normalized name: Paroxetine Tablets
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine tablets (20 mg)
Study: 9796960
Drug: Intravenous mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mesna
Study: 9796960
Drug: Oral mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mesna
Study: 9796960
Drug: Both i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both i.v. and oral mesna
Study: 2650897
Drug: 15 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg.kg‐1 rectal methohexitone
Study: 2650897
Drug: 20 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg.kg‐1 rectal methohexitone
Study: 2650897
Drug: 25 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg.kg‐1 rectal methohexitone
Study: 2650897
Drug: 30 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg.kg‐1 rectal methohexitone
Study: 2650897
Drug: 15 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg.kg‐1 and 20 mg.kg‐1 rectal methohexitone
Study: 1096630
Drug: 1% tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tetracycline ointment
Study: 1096630
Drug: 1% rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% rifampicin ointment
Study: 1096630
Drug: 5% boric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% boric acid ointment
Study: 31248663
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon
Study: 19751560
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone
Study: 18547287
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone for 2 weeks and intranasal budesonide for 12 weeks (treatment group)
Study: 16299871
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 1 year after 2 years of treatment)
Study: 14658
Drug: Lorazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (4 mg)
Study: 12006794
Drug: Flumazenil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.5 mg) administered to seven benzodiazepine-treated patients
Study: 7473011
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl (TTC) 10 mg/ml for 1 minute
Study: 7473011
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl (TTC) 10 mg/ml for 4 minutes
Study: 7473011
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl (TTC) 100 mg/ml for 1 minute
Study: 7473011
Drug: Tetracycline HCl
Normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline HCl (TTC) 100 mg/ml for 4 minutes
Study: 6161804
Drug: Oral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis with broad spectrum tetracycline (Group B)
Study: 6161804
Drug: Infusion prophylaxis
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion prophylaxis (Group C)
Study: 25294223
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group A)
Study: 27416975
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin maintenance therapy (intravesical instillations once a week for 3 weeks at 3, 6, 12 and 18 months after induction)
Study: 27416975
Drug: Non-maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-maintenance group (bacillus Calmette-Guérin induction therapy only)
Study: 27416975
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guérin maintenance therapy
Study: 25661190
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone furoate
Study: 19875277
Drug: Transdermal tulobuterol
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal tulobuterol (2mg) combined with inhaled tiotropium (18microg)
Study: 19875277
Drug: Inhaled tiotropium
Normalized name: tiotropium Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tiotropium (18microg)
Study: 18412932
Drug: MXR 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MXR 1500 mg once daily after dinner
Study: 18412932
Drug: MIR 500
Normalized name: Dextran-coated, nanoparticle-conjugated stabilized synthetic antisense oligonucleotide targeting miR-10b
DrugBank: TTX-MC138 (DB18628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIR 500 mg thrice daily after meals
Study: 16319559
Drug: Therapist‐administered programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist‐administered programme
Study: 12566477
Drug: Selenium supplement
Normalized name: Selenium supplement
DrugBank: Selenious acid (DB11127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplement (200 micro g) for 20 weeks
Study: 1721787
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug (quinine/quinidine/cinchonine) high dose regimen
Study: 1721787
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug (quinine/quinidine/cinchonine) low dose regimen
Study: 6416399
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin 100 mg administered eight hourly
Study: 6416399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal indomethacin and cryoanalgesia
Study: 6416399
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular opiate analgesia
Study: 22829919
Drug: Monthly sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sulfadoxine-pyrimethamine and two doses of azithromycin (AZI-SP)
Study: 31063503
Drug: Control (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (two doses of sulfadoxine-pyrimethamine)
Study: 26458336
Drug: Cilostazol treatment
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol treatment after 90 days
Study: 25073942
Drug: Decompression with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decompression with Wallis implant
Study: 21785897
Drug: 15 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/kg of charcoal-barbecued meat (experiment 1)
Study: 21785897
Drug: 30 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/kg of charcoal-barbecued meat (experiment 2)
Study: 19735233
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR (all doses)
Study: 15843763
Drug: Stimulant +
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant + fluvoxamine (STIM/FLV)
Study: 15843763
Drug: Stimulant +
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant + placebo (STIM/PL)
Study: 2254498
Drug: Hypnotic induction
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic induction at the beginning of each session
Study: 7001491
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg proquazone per day
Study: 7001491
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg proquazone per day
Study: 25675721
Drug: Meldonium 1000
Normalized name: meldonium
DrugBank: Meldonium (DB13723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meldonium 1000 mg/day for 3 months during winter
Study: 19422623
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of paroxetine
Study: 8021700
Drug: Hydroquinine hydrobromide
Normalized name: hydroquinine
DrugBank: Hydroquinine (DB13718)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinine hydrobromide (300 mg/day)
Study: 2605070
Drug: i.v. omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. omeprazole 40 mg 1 h before surgery
Study: 2605070
Drug: i.v. omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. omeprazole 40 mg 3 h before surgery
Study: 163625
Drug: Intensive psychosocial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive psychosocial inhospital treatment (mean length of stay 30 days)
Study: 27161546
Drug: Fimasartan 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 120 mg
Study: 30882901
Drug: Localized index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Localized index node removal after neoadjuvant immunotherapy
Study: 23138384
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (imaging delay 4 s, 48 ml contrast medium)
Study: 23138384
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (imaging delay 8 s, 64 ml contrast medium)
Study: 23138384
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (imaging delay 12 s, 80 ml contrast medium)
Study: 16650679
Drug: Ophthalmic care
Normalized name: atropine sulfate Ophthalmic Solution [Atropine-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic care personnel (including retina specialists, general ophthalmologists, nurses, and photographers) reading digital fundus images without additional training
Study: 11288794
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/daily)
Study: 8308716
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) capsules containing 20.0 mg
Study: 8308716
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) capsules containing 40.0 mg
Study: 8308716
Drug: Conventional ISDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ISDN tablets (5.0 mg each)
Study: 31680344
Drug: Lateral/panoramic view
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral/panoramic view capsule (CapsoCam Plus)
Study: 31680344
Drug: Axial view
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axial view capsule (PillCam SB3)
Study: 28836993
Drug: Flucloxacillin 500
Normalized name: cloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 500 mg four times daily and placebo
Study: 28836993
Drug: Flucloxacillin 500
Normalized name: cloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 500 mg four times daily and phenoxymethylpenicillin 500 mg four times daily
Study: 11454883
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily
Study: 16135166
Drug: Nedocromil (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil (8 mg)
Study: 9374925
Drug: Sulphasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine (SSZ) 2000 mg daily (maximum 3000 mg)
Study: 9374925
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 mg weekly (maximum 15 mg)
Study: 9374925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulphasalazine and methotrexate (COMBI)
Study: 1525791
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF (750 mg twice daily)
Study: 1617044
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg three times daily)
Study: 3903579
Drug: Oral ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ritodrine therapy
Study: 24636287
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 0.5 mg/day
Study: 29767743
Drug: Low-fat yogurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat yogurt (339 g)
Study: 29767743
Drug: Soy pudding
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy pudding (324 g)
Study: 22607109
Drug: Latanoprost 50
Normalized name: Latanoprost 50 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 50 μg/mL
Study: 22607109
Drug: Latanoprost 75
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 75 μg/mL
Study: 22607109
Drug: Latanoprost 100
Normalized name: latanoprost 100 % MISCELL OIL (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 100 μg/mL
Study: 22607109
Drug: Latanoprost 125
Normalized name: latanoprost 125 MCG per 2.5 ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 125 μg/mL
Study: 21121402
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 mcg, 6 hourly, max 4 doses)
Study: 17407170
Drug: Oral caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral caffeine (480 mg) intake
Study: 16363297
Drug: Small volume
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small volume at high concentration (5 mL of 0.75% levobupivacaine)
Study: 16363297
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume at low concentration (10 mL of 0.375% levobupivacaine)
Study: 10775784
Drug: Three-component blood-stage
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-component blood-stage malaria vaccine (recombinant proteins MSP1, MSP2, RESA with Montanide ISA720 adjuvant), injected twice (four weeks apart)
Study: 8685289
Drug: In‐patient treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In‐patient treatment with psychoeducation for parents followed by out‐patient psychosocial intervention
Study: 1519714
Drug: Phenytoin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (5 mg.kg‐1)
Study: 1519714
Drug: Tubocurarine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine (3 mg)
Study: 6524312
Drug: Phenylephrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine treatment
Study: 31232721
Drug: Vaginal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estrogen (via ring or cream)
Study: 11461801
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: 18036873
Drug: Verteporfin infusion
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin infusion followed by standard light application at 15 minutes
Study: 18036873
Drug: Verteporfin infusion
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin infusion followed by delayed light application at 30 minutes
Study: 16282835
Drug: PAX +
Normalized name: diphenhydramine hydrochloride Topical Spray [Derma-Pax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAX + sulpiride (100 mg/d)
Study: 16282835
Drug: PAX (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAX (10-40 mg/d)
Study: 7744584
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy and endocrine manipulation for node-negative breast cancer
Study: 7744584
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy for node-positive disease
Study: 7744584
Drug: Delayed reintroduction
Normalized name: INTRODUCTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed reintroduction of chemotherapy after initial cytotoxic treatment for node-positive disease
Study: 7744584
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment for breast cancer
Study: 31668965
Drug: Renshen Yangrong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renshen Yangrong Tang (RSYRT) herbal extract granules, taken twice a day for six weeks.
Study: 31668965
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (low dose of a single herb - huangqi, taken twice a day for six weeks).
Study: 31703669
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment of HCV in PWID, which includes testing for HCV, assessing liver fibrosis, counselling, treatment delivery, follow-up, and evaluation in integrated substance use disorder treatment clinics.
Study: 31703669
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care involving referral to further diagnostics, treatment, and treatment follow-up in a hospital outpatient clinic.
Study: 31703669
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment of HCV in PWID.
Study: 26020764
Drug: Baseline fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline fasting plasma glucose value increase by 1 mmol/L
Study: 26020764
Drug: Baseline fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline fasting plasma glucose value increase by 1 mmol/L (after adjustment)
Study: 24016248
Drug: Statin-benzafibrate combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-benzafibrate combination therapy (atorvastatin 20 mg QN + bezafibrate 200 mg BID)
Study: 24016248
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy (atorvastatin 20 mg QN or equivalent)
Study: 24016248
Drug: Statin-benzafibrate combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-benzafibrate combination therapy
Study: 18596116
Drug: Amiloride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10 mg daily for 6 weeks)
Study: 18596116
Drug: Alternate psychotropic
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate psychotropic medications (control group)
Study: 12352887
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution (200 mg every 12 hr)
Study: 12352887
Drug: Intravenous/oral fluconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/oral fluconazole (400 mg every 24 hr)
Study: 12352887
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution
Study: 12352887
Drug: Intravenous/oral fluconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/oral fluconazole
Study: 8852867
Drug: 10-mg baclofen
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg baclofen
Study: 8852867
Drug: 20-mg baclofen
Normalized name: baclofen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg baclofen
Study: 1839722
Drug: Chlorhexidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine treatment (ethyl cellulose containing chlorhexidine)
Study: 6662171
Drug: slow-release disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release disopyramide phosphate (DR) 300 mg twice daily
Study: 6662171
Drug: long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: long-acting propranolol (PR) 1 X 160 mg daily
Study: 24552555
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care + brief ACT-based intervention (five group therapy sessions integrating educational topics on heart-healthy behaviours with acceptance and mindfulness skills)
Study: 22136711
Drug: 8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/d of fish oil (1.6 g/d EPA+DHA; n=17)
Study: 22136711
Drug: 8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/d of oxidised fish oil (1.6 g/d EPA+DHA; n=18)
Study: 22136711
Drug: 8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/d of high-oleic sunflower oil (n=19)
Study: 22136711
Drug: Both fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both fish oil groups (8 g/d of fish oil and 8 g/d of oxidised fish oil)